{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:41Z","timestamp":1787026961932,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01760","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T05:23:12Z","timestamp":1598592192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin"],"prefix":"10.3389","volume":"10","author":[{"given":"Alexandre","family":"G\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Van-Obberghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Fresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Muzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Parassol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Boscagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Borchiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"B1","first-page":"180","article-title":"Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma.","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis.","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy.","volume":"9","author":"Palla","year":"2016","journal-title":"Case Rep Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/cmr.0000000000000392","article-title":"case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.","volume":"27","author":"Yuki","year":"2017","journal-title":"Melanom Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.14740\/jh507","article-title":"Bone Marrow findings of immune-mediated pure red cell aplasia following anti-programmed cell death receptor-1 therapy: a report of two cases and review of literature.","volume":"8","author":"Le Aye","year":"2019","journal-title":"J Hematol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review.","volume":"11","author":"Omar","year":"2020","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors.","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia.","volume":"128","author":"Means","year":"2016","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia.","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol."},{"key":"B10","first-page":"142","article-title":"Role of gammadeltaT cells in pathogenesis of acquired pure red cell aplastic anemia.","volume":"15","author":"Liu","year":"2007","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."},{"key":"B11","year":"","journal-title":"Opdivo\u2013Product Information."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/s2352-302630175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"B13","year":"2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajh.21354","article-title":"Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group.","volume":"84","author":"Hirokawa","year":"2009","journal-title":"Am J Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol Immunother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMc1509362","article-title":"Immunotherapy-associated hemolytic anemia with pure red-cell aplasia.","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.leukres.2005.02.018","article-title":"Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.","volume":"29","author":"Au","year":"2005","journal-title":"Leuk Res."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4818.4818","article-title":"Adult patients with acquired pure red cell aplasia: treated by cyclosporine a and\/or corticosteroids\u2013single center experience.","volume":"128","author":"Wu","year":"2016","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T05:23:15Z","timestamp":1598592195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":19,"alternative-id":["10.3389\/fonc.2020.01760"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01760","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"article-number":"1760"}}